SG11201507974RA - Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists - Google Patents

Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists

Info

Publication number
SG11201507974RA
SG11201507974RA SG11201507974RA SG11201507974RA SG11201507974RA SG 11201507974R A SG11201507974R A SG 11201507974RA SG 11201507974R A SG11201507974R A SG 11201507974RA SG 11201507974R A SG11201507974R A SG 11201507974RA SG 11201507974R A SG11201507974R A SG 11201507974RA
Authority
SG
Singapore
Prior art keywords
biomarkers
inflammatory disorders
integrin antagonists
gastrointestinal inflammatory
beta7 integrin
Prior art date
Application number
SG11201507974RA
Inventor
Lauri Diehl
Mary Keir
Meina Tao Tang
Xiaohui Wei
Marna B Williams
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG11201507974RA publication Critical patent/SG11201507974RA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Chemical Kinetics & Catalysis (AREA)
SG11201507974RA 2013-03-27 2014-03-26 Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists SG11201507974RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361805860P 2013-03-27 2013-03-27
US201361914619P 2013-12-11 2013-12-11
PCT/US2014/031825 WO2014160753A1 (en) 2013-03-27 2014-03-26 Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists

Publications (1)

Publication Number Publication Date
SG11201507974RA true SG11201507974RA (en) 2015-10-29

Family

ID=51625486

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507974RA SG11201507974RA (en) 2013-03-27 2014-03-26 Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists

Country Status (14)

Country Link
US (3) US20160209426A1 (en)
EP (3) EP3933401A3 (en)
JP (4) JP6615745B2 (en)
KR (1) KR102175688B1 (en)
CN (1) CN105143876B (en)
AU (3) AU2014241552B2 (en)
BR (1) BR112015024856A2 (en)
CA (1) CA2904095A1 (en)
HK (1) HK1218442A1 (en)
IL (2) IL241185B (en)
MX (1) MX2015011765A (en)
RU (1) RU2015145610A (en)
SG (1) SG11201507974RA (en)
WO (1) WO2014160753A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939246A1 (en) 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
CA2969326A1 (en) * 2014-12-02 2016-06-09 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
CA2916283A1 (en) * 2015-01-09 2016-07-09 Pfizer Inc. Dosage regimen for madcam antagonists
CA2972099A1 (en) * 2015-02-26 2016-09-01 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
CN108139385A (en) * 2015-07-27 2018-06-08 豪夫迈·罗氏有限公司 For the method for diagnose and treat inflammatory bowel disease
CN113893341A (en) * 2015-08-11 2022-01-07 国立大学法人大阪大学 Antibodies
KR102505253B1 (en) * 2016-04-15 2023-03-02 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Methods for Determining and Achieving a Therapeutically Effective Dose of an Anti-CD47 Agent in the Treatment of Cancer
AU2017348369B2 (en) 2016-10-27 2023-09-28 Geneoscopy, Inc. Detection method
AU2018300189A1 (en) 2017-07-14 2020-01-30 Pfizer, Inc. Antibodies to MAdCAM
CN107478563A (en) * 2017-07-19 2017-12-15 浙江省人民医院 A kind of method based on the double cell factors of Flow cytometry tuberculosis specificity
AU2019276577A1 (en) 2018-06-01 2021-01-14 Geneoscopy, Inc. Detection method
WO2020226498A1 (en) 2019-05-07 2020-11-12 Rijksuniversiteit Groningen Biomarker, kit and method for predicting clinical responsiveness to therapy with an agent that targets alpha4beta7 integrin.
JP2023536158A (en) 2020-07-31 2023-08-23 ジェネンテック， インコーポレイテッド Anti-integrin β7 antibody formulation and device
CN114200143B (en) * 2020-09-18 2024-04-02 上海透景诊断科技有限公司 Application of hemoglobin and transferrin in detecting digestive tract hemorrhage
CA3173754A1 (en) * 2021-09-03 2024-03-02 Pliant Therapeutics, Inc. Therapeutic modulation of integrins
CN116246795B (en) * 2023-05-12 2023-07-21 中国医学科学院北京协和医院 Application of reagent for detecting peripheral blood biomarkers in sample in preparation of product for predicting curative effect of esophageal cancer chemotherapy

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4256833A (en) 1979-01-08 1981-03-17 Majid Ali Enzyme immunoassay for allergic disorders
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226A (en) 1988-04-28 1989-10-29 Univ Leland Stanford Junior RESEPTORDETERMINANTER I ANTI-T-CELLER FOER BEHANDLING AV AUTOIMMUNSJUKDOM.
ATE135397T1 (en) 1988-09-23 1996-03-15 Cetus Oncology Corp CELL CULTIVATION MEDIUM FOR INCREASED CELL GROWTH, TO INCREASE THE LONGEVITY AND EXPRESSION OF THE PRODUCTS
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
ES2062519T5 (en) 1989-03-21 2003-07-16 Immune Response Corp Inc VACCINATION AND METHODS AGAINST DISEASES ORIGINATED FROM PATHOGENIC RESPONSES THROUGH SPECIFIC POPULATIONS OF LYMPHOCYTES T.
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
ATE144793T1 (en) 1989-06-29 1996-11-15 Medarex Inc BISPECIFIC REAGENTS FOR AIDS THERAPY
DE69031919T3 (en) 1989-07-19 2005-01-27 Connetics Corp., Palo Alto T-CELL RECEPTOR PEPTIDES AS A CLEANER FOR AUTOIMMUNE AND BAD DISEASES
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
KR0149181B1 (en) 1990-06-29 1998-08-17 데이비드 알, 맥지 Melanin production by transformed microorganisms
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE69233254T2 (en) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
DE69333807T2 (en) 1992-02-06 2006-02-02 Chiron Corp., Emeryville MARKERS FOR CANCER AND BIOSYNTHETIC BINDEPROTEIN THEREFOR
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19544393A1 (en) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistic herbicidal mixtures
AU2582897A (en) 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
PL209786B1 (en) 1999-01-15 2011-10-31 Genentech Inc Variant of mother polypeptide containing Fc region, polypeptide containing variant of Fc region with altered affinity of Fc gamma receptor binding (Fc R), polypeptide containing variant of Fc region with altered affinity of Fc gamma neonatal receptor binding (Fc Rn), composition, isolated nucleic acid, vector, host cell, method for obtaining polypeptide variant, the use thereof and method for obtaining region Fc variant
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2561164A1 (en) 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and their use
KR101364276B1 (en) 2004-09-03 2014-02-20 제넨테크, 인크. Humanized anti-beta7 antagonists and uses therefor
KR101361905B1 (en) * 2008-05-16 2014-02-21 제넨테크, 인크. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
WO2012135589A1 (en) * 2011-03-31 2012-10-04 Genentech, Inc. Methods of administering beta7 integrin antagonists
WO2014055824A1 (en) * 2012-10-05 2014-04-10 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
KR101819414B1 (en) * 2016-08-10 2018-01-16 스미또모 가가꾸 가부시키가이샤 A polarizing film

Also Published As

Publication number Publication date
JP2019023637A (en) 2019-02-14
EP2979087A1 (en) 2016-02-03
HK1218442A1 (en) 2017-02-17
MX2015011765A (en) 2016-01-15
US20220357343A1 (en) 2022-11-10
CN105143876A (en) 2015-12-09
JP6615745B2 (en) 2019-12-04
IL241185A0 (en) 2015-11-30
IL273930A (en) 2020-05-31
RU2015145610A (en) 2017-05-04
EP2979087A4 (en) 2017-03-15
KR20150134414A (en) 2015-12-01
AU2014241552A1 (en) 2015-10-08
KR102175688B1 (en) 2020-11-06
CN105143876B (en) 2018-04-20
AU2014241552B2 (en) 2018-08-16
JP6740294B2 (en) 2020-08-12
US20200025775A1 (en) 2020-01-23
EP3933401A2 (en) 2022-01-05
EP3495814A2 (en) 2019-06-12
AU2021200422A1 (en) 2021-02-25
EP3495814A3 (en) 2019-07-17
JP7055176B2 (en) 2022-04-15
BR112015024856A2 (en) 2018-04-17
JP2020191883A (en) 2020-12-03
JP2016515705A (en) 2016-05-30
WO2014160753A1 (en) 2014-10-02
EP3933401A3 (en) 2022-04-13
AU2018206728A1 (en) 2018-08-02
JP2022106732A (en) 2022-07-20
CA2904095A1 (en) 2014-10-02
US20160209426A1 (en) 2016-07-21
IL241185B (en) 2020-05-31
AU2018206728B2 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
IL273930A (en) Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
EP2965277A4 (en) Predicting approval of transactions
PL3046470T3 (en) Diagnosing and treating movement disorders
IL239957B (en) Evaluation and assays of pkal-mediated disorders
HK1248769A1 (en) Methods for predicting risk of interstitial pneumonia
SI2976013T1 (en) Methods for assessing erythema
EP2971285A4 (en) Blood biomarkers that predict persistent cognitive dysfunction after concussion
EP2967354A4 (en) Multi-modal pharmaco-diagnostic assessment of brian helath
HK1216546A1 (en) Method of assessing risk of pml pml
SMT201500296B (en) ANTAGONISTS OF THE TRPM8 RECEPTOR
GB201321474D0 (en) Novel biomarkers
HK1226017A1 (en) S1p3 antagonists
GB201309426D0 (en) Biomarkers
HK1221166A1 (en) The treatment of inflammatory disorders
GB201316526D0 (en) Biomarkers
GB201308077D0 (en) Biomarkers
GB201316524D0 (en) Biomarkers
GB201312638D0 (en) Biomarkers
GB201313440D0 (en) Characterization of rice
GB201322783D0 (en) Biomarkers
GB201308518D0 (en) Novel Biomarker
GB201304460D0 (en) Biomarker
GB201319761D0 (en) Biomarkers of disease progression
GB201313342D0 (en) Biomarkers
GB201309358D0 (en) Aiding assessment of prognosis in inflammatory disease